Related references
Note: Only part of the references are listed.Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging
A. P. Anandarajah et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
New insights into the experience of fatigue among patients with rheumatoid arthritis: a qualitative study
Stephanie Nikolaus et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis
Elisabeth Lie et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions
F. Van den Bosch et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis
Salvatore D'Angelo et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs
Mariangela Atteno et al.
CLINICAL RHEUMATOLOGY (2010)
Patient-reported Outcomes in a Randomized Trial of Etanercept in Psoriatic Arthritis
Philip J. Mease et al.
JOURNAL OF RHEUMATOLOGY (2010)
Improvements in Quality of Life and Functional Status in Patients With Psoriatic Arthritis Receiving Anti-Tumor Necrosis Factor Therapies
Amr A. Saad et al.
ARTHRITIS CARE & RESEARCH (2010)
Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial
Wolfram Sterry et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments An Observational Study
Annamaria Mazzotta et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2009)
A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue
A. W. R. van Kuijk et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Work disability and health-related quality of life in males and females with psoriatic arthritis
M. Wallenius et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review
U. Kalyoncu et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
P. J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
International Multicenter Psoriasis and Psoriatic Arthritis Reliability Trial for the Assessment of Skin, Joints, Nails, and Dactylitis
Vinod Chandran et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2009)
The use of patient-reported outcomes instruments in registered clinical trials: Evidence from ClinicalTrials.gov
John F. Scoggins et al.
CONTEMPORARY CLINICAL TRIALS (2009)
Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study
Annamaria Mazzotta et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2009)
Psoriatic Arthritis Spondylitis Radiology Index: A Modified Index for Radiologic Assessment of Axial Involvement in Psoriatic Arthritis
Ennio Lubrano et al.
JOURNAL OF RHEUMATOLOGY (2009)
OMERACT 9-9th International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials
Peter Tugwell et al.
JOURNAL OF RHEUMATOLOGY (2009)
Progress on Incorporating the Patient Perspective in Outcome Assessment in Rheumatology and the Emergence of Life Impact Measures at OMERACT 9
John R. Kirwan et al.
JOURNAL OF RHEUMATOLOGY (2009)
Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study
Philip J. Mease et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
Alice Gottlieb et al.
LANCET (2009)
Involvement, satisfaction and unmet health care needs in patients with psoriatic arthritis
Y. -Y. Leung et al.
RHEUMATOLOGY (2009)
Health care utilization in patients with spondyloarthropathies
J. A. Singh et al.
RHEUMATOLOGY (2009)
Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor α
F. Conti et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis
A. Spadaro et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
The comparative one-year performance of anti-tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis:: Results from a longitudinal, observational, multicenter study
Marte Schrumpf Heiberg et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis
Andrew J. Holman et al.
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL (2008)
Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis
M. R. Bongiorno et al.
Dermatologic Therapy (2008)
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy
I. Olivieri et al.
RHEUMATOLOGY (2008)
Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs
F. Cantini et al.
RHEUMATOLOGY (2008)
Effects of a modular behavioural arthritis education programme: a pragmatic parallel-group randomized controlled trial
A. Hammond et al.
RHEUMATOLOGY (2008)
The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis
A. P. Anandarajah et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients:: results from the South Swedish Arthritis Treatment Group register
L. E. Kristensen et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate
Raffaele Scarpa et al.
CLINICAL RHEUMATOLOGY (2008)
A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis
Alan J. Kivitz et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2007)
Sensitivity and specificity of plain radiographic features of peripheral enthesopathy at major sites in psoriatic arthritis
P. S. Helliwell et al.
SKELETAL RADIOLOGY (2007)
Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics
Marina Papoutsaki et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study
M. S. Heiberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study
G. Saviola et al.
RHEUMATOLOGY (2007)
Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis
Helena Marzo-Ortega et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning
Tanja A. Stamm et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate
J. Gratacos et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial
A. Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Efalizumab for the treatment of psoriatic arthritis
Kim A. Papp et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2007)
Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial
D. D. Gladman et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Adalimumab for long-term treatment of psoriatic arthritis - Forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial
Dafna D. Gladman et al.
ARTHRITIS AND RHEUMATISM (2007)
Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis
N. Inanc et al.
CLINICAL RHEUMATOLOGY (2007)
Analgesic and disease modifying effects of interferential current in psoriatic arthritis
UA Walker et al.
RHEUMATOLOGY INTERNATIONAL (2006)
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
CE Antoni et al.
ARTHRITIS AND RHEUMATISM (2005)
Psoriatic arthritis assessment tools in clinical trials
PJ Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
SP McKenna et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Assessment of patients with psoriatic arthritis - A review of currently available measures
DD Gladman et al.
ARTHRITIS AND RHEUMATISM (2004)
Incorporating the patient's perspective into drug development and communication: An ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the Food and Drug Administration, February 16, 2001
C Acquadro et al.
VALUE IN HEALTH (2003)
The estimation of a preference-based measure of health from the SF-36
J Brazier et al.
JOURNAL OF HEALTH ECONOMICS (2002)
Development and validation of a self-efficacy scale for use in British patients with rheumatoid arthritis (RASE)
S Hewlett et al.
RHEUMATOLOGY (2001)
Understanding the adoption of arthritis self-management: stages of change profiles among arthritis patients
FJ Keefe et al.
PAIN (2000)
Share Paper
